| Identification | Back Directory | [Name]
2,9,10-Trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol | [CAS]
3621-38-3 | [Synonyms]
Neprotin
Neprotine
Yatrorizine
Jatrorrhizin
Jateorhizine
Jateorrhizine
jatrorrhizine
NEPROTINE HCL
YATROIZINE HCL
NEPROTINE IODIDE
JATRORRHIZINE(P)
JATRORRHIZINE HCL
YATROIZINE IODIDE
DehydrocorypalMine
2,9,10-trimethoxy-
JATRORRHIZINE IODIDE
JATRORRHIZINE CHLORIDE
JATRORRHIZINE STANDARD 98+% BY HPLC
Jatrorrhizine
See J210900 or J210910
5,6-Dihydro-3-hydroxy-2,9,10-trimethoxyberbinium
Dibenzo[a,g]quinolizinium, 5,6-dihydro-3-hydroxy-
7,8,13,13α-Tetradehydro-3-hydroxy-2,9,10-trimethoxyberbinium
Jatrorrhizine iodide, 98%, from Mahonia fortunei (Lindl.) Fedde
5,6-Dihydro-3-hydroxy-2,9,10-trimethoxydibenzo[a,g]quinolizinium
2,9,10-Trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol
3-Hydroxy-2,9,10-trimethoxy-5,6-dihydroisoquinolino-[3,2-a]isoquinolin-7-ium
2,9,10-Trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol USP/EP/BP
Jatrorrhizine
2,9,10-Trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol | [EINECS(EC#)]
222-817-3 | [Molecular Formula]
C20H20INO4 | [MDL Number]
MFCD00189429 | [MOL File]
3621-38-3.mol | [Molecular Weight]
465.28 |
| Chemical Properties | Back Directory | [Melting point ]
208～210℃ | [storage temp. ]
2-8°C | [solubility ]
Methanol (Slightly, Heated) | [form ]
Solid | [color ]
Orange | [Stability:]
Hygroscopic | [InChIKey]
MXTLAHSTUOXGQF-UHFFFAOYSA-O |
| Hazard Information | Back Directory | [Description]
An alkaloid from Mahonia nepalensis DC. (Syn. Berberis nepalensis Spreng), this
base is optically inactive and forms garnet-red crystals which decompose on heat_x0002_ing. The base contains 3.5 mole of H20 and still retains 1 mole even or prolonged
drying at 100°C in vacuo. The salts are said to be orange or yellow. | [Uses]
Jatrorrhizine, is an alkaloid extract from the Berberidaceae family of plants displaying antioxidant activity. | [Definition]
ChEBI: Jatrorrhizine is an alkaloid. | [in vivo]
Jatrorrhizine (intraperitoneal?injection; 5, 10, 20 mg/kg) can significantly reduce the duration of immobility when compared with vehicle control group in tail suspension test (TST)[2]. | Animal Model: | Male ICR albino mice[2] | | Dosage: | 5, 10, 20 mg/kg | | Administration: | Intraperitoneal?injection; 5, 10, 20 mg/kg | | Result: | Reduced immobility period in tail suspension test. |
| [target]
LDL | P450 (e.g. CYP17) | NOS | COX | 5-HT Receptor | HMG-CoA Reductase | [IC 50]
AChE | [References]
Chatterjee., Sci. & Cult., 7,619 (1942)
Chatterjee.,J. Amer. Pharm. Assoc., 33,205,210 (1944) |
|
|